If you’re looking for big returns, then it could be worth checking out the small side of the market.
That’s because in exchange for higher risk, investors have the potential for higher rewards.
For example, the small cap ASX share in this article has been tipped to provide investors with a return that is more than double the historic market return.
Let’s see what analysts at Bell Potter are saying about this small cap.
Which small cap ASX share is a buy?
According to a note out of Bell Potter, following a change of analyst, the broker has reaffirmed its buy rating and 29 cents price target on Capitol Health Ltd (ASX: CAJ) shares.
Based on its current share price of 24.5 cents, this implies potential upside of 18% for investors over the next 12 months.
In addition, the broker is expecting the medical imaging company to pay fully franked dividends of 1 cent per share in FY 2024, FY 2025, and FY 2026. This will mean dividend yields of 4.1% each year, boosting the total potential return to over 22%.
To put that into context, a $10,000 would be worth approximately $12,200 in 12 months if Bell Potter’s recommendation proves accurate.
It is also more than double the historical return of the share market, which sits at around 10% per annum.
Why is it bullish?
The note reveals that Bell Potter has boosted its revenue estimates for the coming years. This is to reflect the normalising of volumes and pricing growth rates. And while the broker expects inflationary pressures to weigh on margins in the near term, it appears to believe that this is more than priced into the small cap ASX share’s valuation at present. It commented:
On the transfer of coverage, we have reviewed our earnings estimates. Across FY24e â FY26e, we have increased our revenue estimates by c.1.6% / c.4.7% / c.7.9% driven by normalising volume and pricing growth rates across DI Services and Benefits. However, we expect inflationary pressures to dampen the recovery in operating margins and a lower plateau than previous estimates with margins levelling out at c.22% by FY28e.
This leads to a cut in earnings expectations of c.-8% / c-4.8% / c.- 13.4%. We have upgraded our blended DCF / EV / EBITDA valuation by c.3.6% to $0.29 / sh, reflecting adjustments in our valuation parameters. Catalysts for the share price include continued positive momentum in the Medicare data and M&A activity.
The post Buy this cheap small cap ASX share for a very big return appeared first on The Motley Fool Australia.
Should you invest $1,000 in Capitol Health Limited right now?
Before you buy Capitol Health Limited shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Capitol Health Limited wasn’t one of them.
The online investing service heâs run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
See The 5 Stocks
*Returns as of 5 May 2024
More reading
- 3 top ASX 300 dividend shares to buy now for $3,000 a month in passive income
- 3 things about Qantas stock every smart investor knows
- Which ASX biotech shares are pioneering the future of medicine?
- The little-known ASX tech stock that could rise 25% in a year
- ASX investors may choose supermarkets over Wesfarmers shares after ACCC inquiry: broker
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
Leave a Reply